Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib

Kim, Dae-ha; Min, Gee ho; Lee, Dong-won; Ahn, Ke Ryun; Kim, Ji Hye; Suh, Snag-Jun; Jung, Young Kul; Yim, Hyung Joon

doi:2016.16.1.57

J Liver Cancer > Volume 16(1); 2016 > Article

Case Report

Journal of Liver Cancer 2016;16(1):57-62.
DOI: https://doi.org/10.17998/jlc.16.1.57 Published online March 31, 2016.

Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib

Dae-ha Kim, Gee ho Min, Dong-won Lee, Ke Ryun Ahn, Ji Hye Kim, Snag-Jun Suh, Young Kul Jung, Hyung Joon Yim

Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

Abstract

Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.

Key Words: Carcinoma, Hepatocellular; Drug therapy; Sorafenib; Treatment outcome

NULL